Abstract
Derangement of glucose metabolism is a key feature of T2DM, with the liver and pancreatic β-cells playing a key role in glucose homeostasis. In the postprandial state, glucose is transported into hepatocytes and either metabolized to fatty acids or CO2, or stored as glycogen. Glucose also acts as a key signal in pancreatic β-cells for regulating insulin secretion. Because GLUT2 and GK expressed in liver and β-cells are responsible for sensing glucose levels in the blood, studies on the regulation of these biomolecules are important in understanding glucose homeostasis in vivo. These molecules are known to be regulated either transcriptionally or post-transcriptionally, and recent studies on the structure and function of promoters of these genes have revealed the involvement of various transcriptional factors in their regulation. Here, we review recent progress in elucidating the transcriptional regulation of glucose sensors in the liver and pancreatic β-cells and the relevance to T2DM.
Keywords: Type 2 glucose transporter isoform (GLUT2), Glucokinase (GK), Glucose sensor, Transcription, Liver, Pancreatic βcells
Current Diabetes Reviews
Title: Transcriptional Regulation of Glucose Sensors in Pancreatic β Cells and Liver
Volume: 2 Issue: 1
Author(s): Seung-Soon Im, So-Youn Kim, Ha-il Kim and Yong-Ho Ahn
Affiliation:
Keywords: Type 2 glucose transporter isoform (GLUT2), Glucokinase (GK), Glucose sensor, Transcription, Liver, Pancreatic βcells
Abstract: Derangement of glucose metabolism is a key feature of T2DM, with the liver and pancreatic β-cells playing a key role in glucose homeostasis. In the postprandial state, glucose is transported into hepatocytes and either metabolized to fatty acids or CO2, or stored as glycogen. Glucose also acts as a key signal in pancreatic β-cells for regulating insulin secretion. Because GLUT2 and GK expressed in liver and β-cells are responsible for sensing glucose levels in the blood, studies on the regulation of these biomolecules are important in understanding glucose homeostasis in vivo. These molecules are known to be regulated either transcriptionally or post-transcriptionally, and recent studies on the structure and function of promoters of these genes have revealed the involvement of various transcriptional factors in their regulation. Here, we review recent progress in elucidating the transcriptional regulation of glucose sensors in the liver and pancreatic β-cells and the relevance to T2DM.
Export Options
About this article
Cite this article as:
Im Seung-Soon, Kim So-Youn, Kim Ha-il and Ahn Yong-Ho, Transcriptional Regulation of Glucose Sensors in Pancreatic β Cells and Liver, Current Diabetes Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339906775473581
DOI https://dx.doi.org/10.2174/157339906775473581 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells Derived from Human Exfoliated Deciduous Teeth (SHED) in Neuronal Disorders: A Review
Current Stem Cell Research & Therapy The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances on the Antiatherogenic Effects of HDL-Derived Proteins and Mimetic Peptides
Current Pharmaceutical Design The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Control of Mycobacterium tuberculosis Infection by Glutathione
Recent Patents on Anti-Infective Drug Discovery Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Current Approaches to the Diagnosis of Classical form of Congenital Adrenal Hyperplasia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Future Perspective of Diabetic Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Current Vascular Pharmacology c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery The Gatekeeping Function in Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine